Cargando…

Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV

BACKGROUND: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed. METHOD: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Flue...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoschler, Katja, Maharjan, Sunil, Whitaker, Heather, Southern, Jo, Okai, Blessing, Baldevarona, Janice, Turner, Paul J., Andrews, Nick J., Miller, Elizabeth, Zambon, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054836/
https://www.ncbi.nlm.nih.gov/pubmed/32070679
http://dx.doi.org/10.1016/j.vaccine.2020.02.024
_version_ 1783503265639432192
author Hoschler, Katja
Maharjan, Sunil
Whitaker, Heather
Southern, Jo
Okai, Blessing
Baldevarona, Janice
Turner, Paul J.
Andrews, Nick J.
Miller, Elizabeth
Zambon, Maria
author_facet Hoschler, Katja
Maharjan, Sunil
Whitaker, Heather
Southern, Jo
Okai, Blessing
Baldevarona, Janice
Turner, Paul J.
Andrews, Nick J.
Miller, Elizabeth
Zambon, Maria
author_sort Hoschler, Katja
collection PubMed
description BACKGROUND: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed. METHOD: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Fluenz™) was conducted over three consecutive years (2014/15–2016/17) in 254, 249 and 162 children respectively. Serum responses to vaccine components were measured by Haemagglutination Inhibition (HAI) and anti-A(H1N1)pdm09 Neuraminidase (NAI) assays, stratified according to previous receipt of AS03(B)-adjuvanted A(H1N1)pdm09 pandemic vaccine in 2009/10. Antibody levels to the A(H1N1)pdm09 and H3N2 vaccine components in oral fluids (OF) were explored using an ELISA. FINDINGS: More paired pre- and post-vaccination oral fluids (96%) than paired sera (87%) were obtained. Geometric mean titre rises using HAI assays were limited, with maximum rises seen in year one for both influenza B strains when 39% and 43% of subjects seroconverted (95% confidence interval 33–46% and 36–50%, respectively) and year two for influenza H3N2, when 40% (33–46%) individuals seroconverted. Prior pandemic vaccine receipt resulted in higher pre- and post-vaccination A(H1N1)pdm09 HAI titres and lower pre-and post-vaccination NAI (N1 neuraminidase) titres in all three years. OF results were congruent with HAI results; assay specificity compared to HAI was 88.1 and 71.6 percent, and sensitivity was 86.4 and 74.8 percent respectively for A(H1N1)pdm09 and H3N2. CONCLUSION: In all three study years, vaccination with qLAIV resulted in poor antibody responses. However, OFs are an alternative specimen type that allows self sampling, can easily be obtained from children, and their analysis leads to similar conclusions as classic serology by HAI. Their suitability for seroprevalence studies should be investigated. We demonstrated a sustained effect from prior receipt of the AS03(B)-adjuvanted A(H1N1)pdm09 vaccine, even after repeat vaccination with qLAIV indicating that early exposure to influenza antigens has a significant long lasting effect.
format Online
Article
Text
id pubmed-7054836
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-70548362020-03-10 Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV Hoschler, Katja Maharjan, Sunil Whitaker, Heather Southern, Jo Okai, Blessing Baldevarona, Janice Turner, Paul J. Andrews, Nick J. Miller, Elizabeth Zambon, Maria Vaccine Article BACKGROUND: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed. METHOD: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Fluenz™) was conducted over three consecutive years (2014/15–2016/17) in 254, 249 and 162 children respectively. Serum responses to vaccine components were measured by Haemagglutination Inhibition (HAI) and anti-A(H1N1)pdm09 Neuraminidase (NAI) assays, stratified according to previous receipt of AS03(B)-adjuvanted A(H1N1)pdm09 pandemic vaccine in 2009/10. Antibody levels to the A(H1N1)pdm09 and H3N2 vaccine components in oral fluids (OF) were explored using an ELISA. FINDINGS: More paired pre- and post-vaccination oral fluids (96%) than paired sera (87%) were obtained. Geometric mean titre rises using HAI assays were limited, with maximum rises seen in year one for both influenza B strains when 39% and 43% of subjects seroconverted (95% confidence interval 33–46% and 36–50%, respectively) and year two for influenza H3N2, when 40% (33–46%) individuals seroconverted. Prior pandemic vaccine receipt resulted in higher pre- and post-vaccination A(H1N1)pdm09 HAI titres and lower pre-and post-vaccination NAI (N1 neuraminidase) titres in all three years. OF results were congruent with HAI results; assay specificity compared to HAI was 88.1 and 71.6 percent, and sensitivity was 86.4 and 74.8 percent respectively for A(H1N1)pdm09 and H3N2. CONCLUSION: In all three study years, vaccination with qLAIV resulted in poor antibody responses. However, OFs are an alternative specimen type that allows self sampling, can easily be obtained from children, and their analysis leads to similar conclusions as classic serology by HAI. Their suitability for seroprevalence studies should be investigated. We demonstrated a sustained effect from prior receipt of the AS03(B)-adjuvanted A(H1N1)pdm09 vaccine, even after repeat vaccination with qLAIV indicating that early exposure to influenza antigens has a significant long lasting effect. Elsevier Science 2020-03-10 /pmc/articles/PMC7054836/ /pubmed/32070679 http://dx.doi.org/10.1016/j.vaccine.2020.02.024 Text en Crown Copyright © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Hoschler, Katja
Maharjan, Sunil
Whitaker, Heather
Southern, Jo
Okai, Blessing
Baldevarona, Janice
Turner, Paul J.
Andrews, Nick J.
Miller, Elizabeth
Zambon, Maria
Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title_full Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title_fullStr Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title_full_unstemmed Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title_short Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with LAIV
title_sort use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2–16 years after successive annual vaccinations with laiv
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054836/
https://www.ncbi.nlm.nih.gov/pubmed/32070679
http://dx.doi.org/10.1016/j.vaccine.2020.02.024
work_keys_str_mv AT hoschlerkatja useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT maharjansunil useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT whitakerheather useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT southernjo useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT okaiblessing useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT baldevaronajanice useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT turnerpaulj useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT andrewsnickj useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT millerelizabeth useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv
AT zambonmaria useoftraditionalserologicalmethodsandoralfluidstoassessimmunogenicityinchildrenaged216yearsaftersuccessiveannualvaccinationswithlaiv